Triple Negative Breast Cancer : give us access to treatments to stay alive !
Triple Negative Breast Cancer : give us access to treatments to stay alive !
Проблема
We are @triplyata_vmeste, a collective of daughters, wives, sisters, mothers, friends, relatives and patients affected by triple-negative breast cancer.
We are launching this petition to ensure access to TRODELVY in Russia and CIS as a whole.
Thousands of young women are diagnosed with metastatic triple-negative breast cancer.
In Russia we have no access to the innovative treatments available elsewhere, metastatic patients still have an outdated protocol based on chemotherapy alone, until their dying breath.
An innovative treatment (TRODELVY) exists to double the life expectancy of these women diagnosed with this particularly aggressive breast cancer.
This treatment is available in the U.S., France, Germany, but is not available in Russia or elsewhere in CIS.
Let's show the need for accessibility to this life-saving treatment by signing this petition!
Despite numerous advances in research, some breast cancers remain difficult to treat. This is the case for one of the most lethal cancers known to man: "triple-negative" breast cancer. This cancer strikes approximately 40,000 women a year, many of whom are young. 30% of patients will metastasize within 3 years of their diagnosis, representing 12,000 patients each year. Once the disease is metastatic, the median survival time in Russia is estimated at 14 months.
There is a treatment to nearly double the life expectancy of women with metastatic triple-negative breast cancer. This treatment is TRODELVY (Sacituzumab Govitecan), produced by the GILEAD Sciences laboratory.
TRODELVY is available in the United States. All American patients are given priority access to benefit from its ability to double the number of precious days left in a woman’s life.
Waiting to benefit from Sacituzumab Govitecan (TRODELVY) is unacceptable for all patients who have arrived at the end of their therapeutic options.
It is impossible for us to remain inactive knowing that waiting will result in the death of these young women with metastatic triple-negative breast cancer and that their children will grow up without a mother.
THIS EMERGENCY IS A QUESTION OF LIFE OR DEATH!
Please help us by signing the petition to Gilead: ACCELERATE THE SUPPLY OF TRODELVY IN RUSSIA (AND IN CIS).
EXTENDING THE LIVES OF WOMEN CANNOT WAIT!
Проблема
We are @triplyata_vmeste, a collective of daughters, wives, sisters, mothers, friends, relatives and patients affected by triple-negative breast cancer.
We are launching this petition to ensure access to TRODELVY in Russia and CIS as a whole.
Thousands of young women are diagnosed with metastatic triple-negative breast cancer.
In Russia we have no access to the innovative treatments available elsewhere, metastatic patients still have an outdated protocol based on chemotherapy alone, until their dying breath.
An innovative treatment (TRODELVY) exists to double the life expectancy of these women diagnosed with this particularly aggressive breast cancer.
This treatment is available in the U.S., France, Germany, but is not available in Russia or elsewhere in CIS.
Let's show the need for accessibility to this life-saving treatment by signing this petition!
Despite numerous advances in research, some breast cancers remain difficult to treat. This is the case for one of the most lethal cancers known to man: "triple-negative" breast cancer. This cancer strikes approximately 40,000 women a year, many of whom are young. 30% of patients will metastasize within 3 years of their diagnosis, representing 12,000 patients each year. Once the disease is metastatic, the median survival time in Russia is estimated at 14 months.
There is a treatment to nearly double the life expectancy of women with metastatic triple-negative breast cancer. This treatment is TRODELVY (Sacituzumab Govitecan), produced by the GILEAD Sciences laboratory.
TRODELVY is available in the United States. All American patients are given priority access to benefit from its ability to double the number of precious days left in a woman’s life.
Waiting to benefit from Sacituzumab Govitecan (TRODELVY) is unacceptable for all patients who have arrived at the end of their therapeutic options.
It is impossible for us to remain inactive knowing that waiting will result in the death of these young women with metastatic triple-negative breast cancer and that their children will grow up without a mother.
THIS EMERGENCY IS A QUESTION OF LIFE OR DEATH!
Please help us by signing the petition to Gilead: ACCELERATE THE SUPPLY OF TRODELVY IN RUSSIA (AND IN CIS).
EXTENDING THE LIVES OF WOMEN CANNOT WAIT!
Петиция закрыта
Расскажите о петиции
Новости этой петиции
Поделиться этой петицией
Петиция создана 26 января 2022 г.